Balcinrenone - AstraZeneca
Alternative Names: AZD-9977Latest Information Update: 23 May 2024
At a glance
- Originator AstraZeneca
- Class Acetamides; Benzoxazines; Cardiovascular therapies; Fluorinated hydrocarbons; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure; Kidney disorders; Renal failure
- Discontinued Cardiovascular disorders; Diabetic nephropathies
Most Recent Events
- 02 May 2024 AstraZeneca initiates a phase I trial (In volunteers) in USA (PO) (NCT06388616)
- 01 May 2024 Phase-II clinical trials in Renal failure (Combination therapy) in Canada and USA (PO) (NCT06350123)
- 29 Apr 2024 AstraZeneca plans a phase I pharmacokinetics trial in hepatic impaired patients and in volunteers in USA in May 2024 (PO) (NCT06388616)